JHS Svendgaard Laboratories Limited , a company listed on Indian stock exchanges, has taken a significant step towards employee engagement and retention. The company's Nomination and Remuneration Committee has approved the grant of 31,30,000 employee stock options (ESOPs) under its newly introduced Employee Stock Option Scheme-2025.

Key Details of the ESOP Grant

Vesting and Exercise Details

The approved ESOP scheme includes the following vesting and exercise provisions:

• Vesting Period: Commences one year from the grant date and extends up to five years
• Exercise Period: Maximum of 5 years from the respective vesting date
• Special Provisions: In case of death or permanent disability of a grantee, the minimum one-year vesting period is waived

Compliance and Regulatory Aspects

The company has confirmed that the ESOP scheme is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. This grant of ESOPs was disclosed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Implications for Employees and Shareholders

The introduction of this ESOP scheme represents a strategic move by JHS Svendgaard Laboratories to align employee interests with those of the company and its shareholders. By offering equity participation, the company aims to motivate and retain key talent, potentially leading to improved performance and long-term value creation.

For existing shareholders, while there may be a potential dilution effect in the future when these options are exercised, the alignment of employee interests with company performance could potentially offset this through improved corporate results.

As the vesting period extends over several years, the full impact of this ESOP grant on the company's financial statements and share structure will unfold gradually. Investors and stakeholders may want to monitor future financial reports for updates on the scheme's implementation and its effects on the company's performance and equity structure.

JHS Svendgaard Laboratories Limited , a prominent player in the FMCG industry, has announced significant leadership and governance decisions following its 21st Annual General Meeting (AGM) held on September 20, 2025.

Nikhil Nanda's Reappointment

The company's shareholders have approved the reappointment of Nikhil Nanda as Managing Director for a five-year term. Nanda's new tenure will commence on July 2, 2025, and continue until the conclusion of the 26th AGM in 2030.

Leadership Profile

Nikhil Nanda, a first-generation entrepreneur, brings over 30 years of experience in the FMCG sector to his role. He holds a Business Management degree with double majors in Finance and Marketing from FORE School of Management, New Delhi. Nanda's entrepreneurial journey began in 1997 when he founded the company, which he successfully took public in 2006 with a $10 million IPO.

Corporate Governance

JHS Svendgaard Laboratories has emphasized its commitment to strong corporate governance by making several key appointments:

1. Statutory Auditors: M/s V.K. Khosla & Co, Chartered Accountants (FRN: 002283N), have been appointed for a five-year term until the 26th AGM in 2030.

2. Secretarial Auditors: M/s Dahiya & Associates, Practicing Company Secretaries (Peer Review certificate No. 6772/2025), have also been appointed for a five-year term until the 26th AGM in 2030.

3. Director Appointment: Mr. Vinay Mittal (DIN: 08232559) has been appointed as a Director, liable to retire by rotation.

Employee Stock Option Scheme

In a move that could potentially align employee interests with company performance, the shareholders have approved the JHS Svendgaard Laboratories Limited - Employee Stock Option Scheme 2025.

AGM Highlights

The 21st AGM, conducted through video conferencing, saw active participation from shareholders. Key resolutions, including the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2025, were passed with overwhelming majority.

These decisions reflect JHS Svendgaard Laboratories' focus on maintaining strong leadership, ensuring robust financial oversight, and aligning employee interests with company growth as it moves forward in the competitive FMCG landscape.